Cogent Biosciences (COGT) Issues 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Cogent Biosciences Provides 2022 Corporate Guidance
January 5, 2022 7:00 AM ESTCAMBRIDGE, Mass. and BOULDER, Colo., Jan. 5, 2022 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided 2021 year-end updates and corporate guidance for 2022.
... More